share_log
Reuters ·  04/29 08:55

AIM ImmunoTech Announces First Dose Level Is Generally Well-Tolerated in Phase 1B/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer

AIM ImmunoTech宣布在Ampligen和Imfinzi作为晚期胰腺癌联合疗法的1B/2期研究中,首剂量水平总体上耐受性良好

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发